Surfactant Therapy

Surfactant therapy is a treatment given to newborns, most often premature babies, whose lungs cannot yet produce enough of a natural substance called surfactant. Without it, the tiny air sacs in the lungs (alveoli) collapse after every breath, making it extremely hard to breathe — a condition called Respiratory Distress Syndrome (RDS). Doctors deliver liquid surfactant directly into the baby’s airway through a thin tube, often within minutes to hours of birth. Most babies show visible improvement in oxygen levels within 15 to 30 minutes. The therapy is one of the most well-studied and effective interventions in neonatal medicine, and it has helped cut RDS-related deaths by more than half since it became standard practice.

What is Surfactant, and Why Does it Matter?

Think of your baby’s lungs as millions of tiny balloons (called alveoli) that inflate with every breath. Surfactant is a slippery, fatty substance that lines the inside of those balloons. It reduces surface tension, which is the force that would otherwise make the walls of the balloon stick together and collapse when air is exhaled.

Without enough surfactant, each balloon collapses at the end of every breath. That means the baby has to work exponentially harder to reopen the air sacs with the next breath, similar to trying to inflate a wet paper bag over and over again. This constant strain leads to poor oxygen exchange, rapid breathing, grunting sounds, and visible chest retractions.

The body typically starts producing adequate surfactant around 34 to 36 weeks of pregnancy. Babies born before this window, especially those arriving before 32 weeks, often don’t have enough of it. That’s where surfactant therapy comes in: it delivers a lab-prepared or animal-derived version of surfactant directly into the baby’s lungs to do the job their own body isn’t ready to do yet.

What is Surfactant Therapy in Neonates?

Surfactant therapy in neonates is a targeted medical treatment used mainly to manage Respiratory Distress Syndrome (RDS) in premature infants. A neonatologist or trained NICU specialist administers liquid surfactant through a thin tube placed into the baby’s windpipe (trachea), allowing the medication to spread across the lung surface and restore normal lung mechanics.

It’s considered one of the most significant advances in neonatal care over the past four decades. Before surfactant replacement became standard in the 1990s, RDS was a leading cause of death among premature infants. Today, with early surfactant administration combined with modern ventilation support, survival rates for even very premature babies have improved dramatically.

Types of Surfactant Therapy in Neonates

Not all surfactant preparations are the same. Neonatologists choose between two broad categories depending on the baby’s condition, gestational age, and hospital protocol.

Natural (Animal-Derived) Surfactants

These are extracted from bovine (cow) or porcine (pig) lung tissue and processed to remove proteins that could trigger an immune reaction, while retaining the phospholipids and surfactant-specific proteins that closely mirror human lung surfactant. Because their composition is so similar to what a baby’s lungs would naturally produce, natural surfactants tend to act faster and are the most widely used option in NICUs today.

Synthetic (Protein-Free or Protein-Analog) Surfactants

These are manufactured in a lab rather than extracted from animal tissue. Newer synthetic formulations now include synthetic peptides that mimic natural surfactant proteins, closing much of the effectiveness gap that older synthetic products had. They’re a useful option for infants whose families prefer to avoid animal-derived products, or in settings where natural surfactant isn’t readily available.

Natural vs. Synthetic Surfactant: A Quick Comparison

Your neonatology team will recommend the option best suited to your baby’s specific clinical picture — this decision is rarely one-size-fits-all.

Why Would a Newborn Need Surfactant Therapy? (Indications)

Surfactant therapy isn’t limited to prematurity alone. Neonatologists consider it for several conditions where lung surfactant is either insufficient or has been disrupted:

1. Respiratory Distress Syndrome (RDS): The most common reason for surfactant administration, seen almost exclusively in premature infants with underdeveloped lungs.
2. Meconium Aspiration Syndrome (MAS): When a baby inhales meconium (their first stool) before or during birth, it can inactivate existing surfactant. Surfactant therapy helps restore normal lung function in these cases.
3. Persistent Pulmonary Hypertension of the Newborn (PPHN): A condition where blood pressure in the lungs’ vessels stays abnormally high after birth. Surfactant therapy can improve oxygenation as part of a broader treatment plan.
4. Pneumonia or Sepsis-Related Lung Injury: Severe infections can damage the surfactant layer, and replacement therapy may support recovery alongside antibiotics.
5. Pulmonary Hemorrhage: In select cases, surfactant can help stabilize lung function after bleeding into the lung tissue.

How Surfactant Therapy Is Given: Methods and Procedure

There are three main techniques used in modern NICUs, and the choice depends on how much respiratory support the baby already needs.

InSurE (Intubate–Surfactant–Extubate)

The baby is briefly intubated, given surfactant, and then extubated back onto non-invasive support such as CPAP (Continuous Positive Airway Pressure). This minimizes the time spent on a ventilator, which helps reduce the risk of ventilator-associated lung injury.

LISA / MIST (Less-Invasive Surfactant Administration / Minimally Invasive Surfactant Therapy)

A thin, flexible catheter delivers surfactant into the airway while the baby breathes on their own with CPAP support — no full intubation required. Growing clinical evidence favors LISA for spontaneously breathing preterm infants, as it’s associated with lower rates of chronic lung disease compared to traditional intubation-based methods.

Standard Intubation with Mechanical Ventilation

For babies who are already on a ventilator due to more severe respiratory failure, surfactant is given through the existing endotracheal tube, and ventilator support continues afterward.

What Happens During the Procedure

• The baby is positioned carefully, and heart rate and oxygen saturation are monitored continuously.
• Surfactant is administered in small, measured doses over a few minutes.
• The care team watches closely for a brief period where oxygen requirements may fluctuate as the medication spreads through the lungs.
• Most babies show measurable improvement in breathing effort and oxygen levels within 15 to 30 minutes.

Benefits of Surfactant Therapy for Premature Infants

• Improves lung compliance: The lungs become easier to inflate, meaning the baby doesn’t have to work as hard to breathe.
• Reduces mortality and severe complications: Clinical evidence consistently shows lower death rates and fewer serious complications when surfactant is given early.
• Lowers the risk of ventilator-induced lung injury: By reducing how much ventilator support is needed, surfactant therapy helps protect delicate lung tissue from long-term damage.
• Improves oxygen exchange: Better gas exchange means more stable oxygen and carbon dioxide levels, which supports healthy brain and organ development.
• Shortens NICU dependency on invasive ventilation: Especially with LISA/MIST techniques, babies often transition to less invasive breathing support sooner.

Equipment Used During Surfactant Administration

Who Typically Needs Surfactant Therapy?

• Babies born before 34 weeks of gestation, who carry the highest risk of RDS due to underdeveloped surfactant-producing cells.
• Any newborn diagnosed with RDS, regardless of exact gestational age, if breathing difficulty is confirmed on clinical exam and chest X-ray.
• Infants with MAS or PPHN who show poor oxygenation despite initial supportive care.
• Babies from multiple pregnancies (twins, triplets), who are statistically more likely to be born early.
• Infants of mothers with diabetes, since maternal diabetes can delay fetal lung maturity even at later gestational ages.
• Babies delivered by C-section without labor, since the hormonal changes of labor help trigger surfactant production, and skipping labor can leave levels lower than expected.

When Should Surfactant Be Given?

Timing matters. Neonatology guidelines generally favor early administration — ideally within the first two hours of life for babies showing signs of RDS — because early treatment is linked to better outcomes than waiting until symptoms become severe. That said, surfactant can still provide meaningful benefit if given later, whenever a baby’s clinical picture calls for it.

Signs that prompt a neonatologist to consider surfactant therapy include:

• Rapid breathing (tachypnea) shortly after birth
• Grunting with each breath
• Visible retractions of the chest wall
• Bluish tinge to the skin (cyanosis) from low oxygen
• Chest X-ray findings consistent with RDS

How Many Doses are Needed?

Most infants respond well to a single dose, but it’s common for babies to need a second or even third dose, typically spaced six to twelve hours apart, if oxygen requirements remain elevated or symptoms persist. The care team reassesses after each dose using oxygen saturation trends, blood gas results, and clinical exam findings before deciding whether another dose is warranted.

Diagnostic Assessments Used Alongside Surfactant Therapy

Chest X-Rays

Chest imaging helps confirm the diagnosis of RDS, checks how well the lungs have expanded after treatment, and screens for complications such as pneumothorax (air leak) or atelectasis (partial lung collapse).

Blood Gas Analysis

Regular blood samples measure oxygen and carbon dioxide levels, giving the care team an objective way to judge whether the current treatment plan is working or needs adjustment.

Continuous Clinical Monitoring

Nurses and doctors track breathing rate, effort, and breath sounds around the clock, since subtle changes can signal the need for additional intervention.

Pulmonary Function Testing

Less commonly used in very small infants, but where available, these tests offer detailed data on lung compliance and gas exchange efficiency.

Biochemical Markers

In pregnancies where premature delivery is anticipated, doctors may check the lecithin/sphingomyelin (L/S) ratio in amniotic fluid to estimate fetal lung maturity and predict RDS risk before birth.

Special Situations to Be Aware Of

• Multiple births: Twins and triplets are more likely to be born prematurely, increasing the likelihood that one or more babies will need surfactant support.
• Infants of diabetic mothers: Even babies born closer to full term can have delayed lung maturity if the mother has diabetes during pregnancy.
• Planned C-sections without labor: Because labor hormones support lung maturity, elective C-sections performed before 39 weeks carry a higher chance of respiratory difficulty.

What Parents Can Expect: A Realistic Timeline

Every baby’s course is different, but here’s a general picture of what families often experience:

1. Within minutes to hours of birth: If RDS symptoms appear, the NICU team evaluates the baby and may recommend surfactant therapy.
2. During the procedure: Administration itself typically takes just a few minutes, though monitoring continues throughout.
3. First 30 minutes after: Oxygen requirements are watched closely, as the lungs begin responding to the treatment.
4. First 24–48 hours: The team monitors for the need of additional doses and gradually weans ventilator or CPAP support as tolerated.
5. Ongoing NICU care: Depending on gestational age and overall health, babies may remain in the NICU for days to weeks for continued growth and monitoring, even after breathing stabilizes.

Parents are almost always encouraged to be present, ask questions, and participate in kangaroo care (skin-to-skin contact) as soon as it’s medically safe — this bonding time supports the baby’s stability and the family’s emotional wellbeing.

Risks and Safety Considerations

Surfactant therapy has an excellent safety record, but like any medical intervention, it isn’t entirely without risk. Possible short-term effects include a brief drop in oxygen saturation during administration, a temporary need for increased ventilator support, or rarely, plugging of the airway tube. Neonatal teams are trained to monitor for and manage these situations quickly, and serious complications are uncommon when the therapy is administered by experienced NICU staff.

Conclusion

Surfactant therapy is one of the true success stories of modern neonatal medicine. What was once one of the leading causes of death in premature infants is now a manageable, well-understood condition, thanks largely to this treatment. For parents, understanding what the therapy does, why it’s needed, and what recovery typically looks like can make an overwhelming NICU experience feel a little more navigable.

If your baby has been diagnosed with RDS or another condition requiring surfactant therapy, your neonatology team will walk you through every step of the process and answer any questions specific to your baby’s situation. Don’t hesitate to ask — no question is too small when it comes to your child’s care.